Compare CTS & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTS | COLL |
|---|---|---|
| Founded | 1896 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | N/A | 2015 |
| Metric | CTS | COLL |
|---|---|---|
| Price | $48.36 | $45.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $51.17 |
| AVG Volume (30 Days) | 158.2K | ★ 484.7K |
| Earning Date | 02-03-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.33% | N/A |
| EPS Growth | ★ 3.07 | N/A |
| EPS | ★ 1.98 | 1.63 |
| Revenue | $531,522,000.00 | ★ $757,067,000.00 |
| Revenue This Year | $5.73 | $26.17 |
| Revenue Next Year | $4.00 | $3.65 |
| P/E Ratio | ★ $24.38 | $28.05 |
| Revenue Growth | 3.61 | ★ 26.34 |
| 52 Week Low | $34.02 | $23.23 |
| 52 Week High | $53.28 | $50.79 |
| Indicator | CTS | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 72.40 | 44.54 |
| Support Level | $46.28 | $45.00 |
| Resistance Level | $49.14 | $49.17 |
| Average True Range (ATR) | 1.06 | 1.97 |
| MACD | 0.35 | -0.31 |
| Stochastic Oscillator | 87.98 | 16.81 |
CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEM) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China; Singapore; the Czech Republic; Taiwan, Denmark, and other countries.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.